UIC-2010-079 – A Novel Prostate Cancer Vaccine

Prostate cancer is the second leading cause of cancer death among men in the US. It is estimated that more than 200,000 new cases are diagnosed every year and approximately 30,000 will die of this disease. This cancer can be diagnosed at an early stage, but there are few effective treatment options for early stage prostate cancer. Currently used hormonal treatments do not address cancer progression. There is an urgent need for disease-modifying immunotherapies to halt the progression of early-stage prostate cancer. UIC researchers have developed a novel Immunotherapy for early stage prostate cancer employing a synthetic peptide which has been clinically validated in 28 patients.This therapeutic peptide exploits the body’s own immune system to mount a selective attack on the prostate tumor cells. In human trials, the peptide has been demonstrated to extend human survival by 5 years or more. UIC scientists have performed full-human genome profiling of patients who have received treatment to identify mechanisms of action and other novel therapeutic targets. Hyunjin Kim hkim227@otm.uic.edu 312355-7843

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More